Cargando…

Impact of COVID-19 in Patients With Severe Alpha-1 Antitrypsin Deficiency: The IMCA1 Study of the EARCO Clinical Research Collaboration

Detalles Bibliográficos
Autores principales:	Parr, David G., Chorostowska-Wynimko, Joanna, Corsico, Angelo, Esquinas, Cristina, McElvaney, Gerard N., Sark, Annelot D., Sucena, Maria, Tanash, Hanan, Turner, Alice M., Miravitlles, Marc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SEPAR. Published by Elsevier España, S.L.U. 2022
Materias:	Scientific Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272568/ https://www.ncbi.nlm.nih.gov/pubmed/35879122 http://dx.doi.org/10.1016/j.arbres.2022.07.002

Ejemplares similares

Protocol for the EARCO Registry: a pan-European observational study in patients with α(1)-antitrypsin deficiency
por: Greulich, Timm, et al.
Publicado: (2020)

Research priorities in α(1)-antitrypsin deficiency: results of a patients' and healthcare providers' international survey from the EARCO Clinical Research Collaboration
por: Barrecheguren, Miriam, et al.
Publicado: (2020)

Clinical and functional characteristics of individuals with alpha-1 antitrypsin deficiency: EARCO international registry
por: Miravitlles, Marc, et al.
Publicado: (2022)

Correction: Clinical and functional characteristics of individuals with alpha-1 antitrypsin deficiency: EARCO international registry
por: Miravitlles, Marc, et al.
Publicado: (2023)

Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications
por: Chapman, Kenneth R, et al.
Publicado: (2018)

The prevalence of bronchiectasis in patients with alpha-1 antitrypsin deficiency: initial report of EARCO
por: Stockley, Robert A., et al.
Publicado: (2023)

Diagnosis and management of α(1)-antitrypsin deficiency in Europe: an expert survey
por: Horváth, Ildikó, et al.
Publicado: (2019)

Demographic and clinical characteristics of patients with α(1)-antitrypsin deficiency genotypes PI*ZZ and PI*SZ in the Spanish registry of EARCO
por: Torres-Durán, María, et al.
Publicado: (2022)

Opinions and Attitudes of Pulmonologists About Augmentation Therapy in Patients with Alpha-1 Antitrypsin Deficiency. A Survey of the EARCO Group
por: Greulich, Timm, et al.
Publicado: (2022)

Targeted screening programmes in COPD: how to identify individuals with α(1)-antitrypsin deficiency
por: Chorostowska-Wynimko, Joanna
Publicado: (2015)

Practice and knowledge about diagnosis and treatment of alpha-1 antitrypsin deficiency in Spain and Portugal
por: Esquinas, Cristina, et al.
Publicado: (2016)

SERPINA1 and More? A Putative Genetic Contributor to Pulmonary Dysfunction in Alpha-1 Antitrypsin Deficiency
por: Jezela-Stanek, Aleksandra, et al.
Publicado: (2023)

Diagnosing α(1)-antitrypsin deficiency: how to improve the current algorithm
por: McElvaney, Noel G.
Publicado: (2015)

The Relationship between Plasma Alpha-1-Antitrypsin Polymers and Lung or Liver Function in ZZ Alpha-1-Antitrypsin-Deficient Patients
por: Sark, Annelot D., et al.
Publicado: (2022)

Quantitative disease progression model of α‐1 proteinase inhibitor therapy on computed tomography lung density in patients with α‐1 antitrypsin deficiency
por: Tortorici, Michael A., et al.
Publicado: (2017)

Clinical considerations in individuals with α(1)-antitrypsin PI*SZ genotype
por: McElvaney, Gerard N., et al.
Publicado: (2020)

Post-Translational Modifications of Circulating Alpha-1-Antitrypsin Protein
por: Lechowicz, Urszula, et al.
Publicado: (2020)

The Multifaceted Effects of Alpha1-Antitrypsin on Neutrophil Functions
por: Janciauskiene, Sabina, et al.
Publicado: (2018)

Is There a Therapeutic Role for Selenium in Alpha-1 Antitrypsin Deficiency?
por: Greene, Catherine M., et al.
Publicado: (2013)

Alpha-1 antitrypsin for cystic fibrosis complicated by severe cytokinemic COVID-19
por: McElvaney, Oliver J, et al.
Publicado: (2021)

New Patient-Centric Approaches to the Management of Alpha-1 Antitrypsin Deficiency
por: Chorostowska-Wynimko, Joanna, et al.
Publicado: (2020)

The prevalence of liver abnormalities in individuals with ZZ Alpha-1 Antitrypsin deficiency
por: McElvaney, OF, et al.
Publicado: (2015)

Liver disease in adults with severe alpha-1-antitrypsin deficiency
por: Tanash, Hanan A., et al.
Publicado: (2019)

Gene targeted therapeutics for liver disease in alpha-1 antitrypsin deficiency
por: McLean, Caitriona, et al.
Publicado: (2009)

The Clinical Course of Severe Alpha-1-Antitrypsin Deficiency in Patients Identified by Screening
por: Hiller, Adriana-Maria, et al.
Publicado: (2022)

Alpha-1 proteinase inhibitors for the treatment of alpha-1 antitrypsin deficiency: safety, tolerability, and patient outcomes
por: Chotirmall, Sanjay H, et al.
Publicado: (2015)

Decline in FEV(1) and hospitalized exacerbations in individuals with severe alpha-1 antitrypsin deficiency
por: Hiller, Adriana-Maria, et al.
Publicado: (2019)

Lung transplantation and survival outcomes in patients with oxygen-dependent COPD with regard to their alpha-1 antitrypsin deficiency status
por: Ekström, Magnus, et al.
Publicado: (2017)

Survival in severe alpha-1-antitrypsin deficiency (PiZZ)
por: Tanash, Hanan A, et al.
Publicado: (2010)

Dysregulated neutrophil function in individuals with alpha-1 antitrypsin deficiency caused by modified membrane cholesterol content.
por: Jundi, Bakr, et al.
Publicado: (2015)

Survival in the Swedish cohort with alpha-1-antitrypsin deficiency, up to the age of 43–45 years
por: Mostafavi, Behrouz, et al.
Publicado: (2019)

Does urinary peptide content differ between COPD patients with and without inherited alpha-1 antitrypsin deficiency?
por: Carleo, Alfonso, et al.
Publicado: (2017)

Liver function in alpha-1-antitrypsin deficient individuals at 37 to 40 years of age
por: Mostafavi, Behrouz, et al.
Publicado: (2017)

Alpha-1 antitrypsin regulates neutrophil reactive oxygen species production via inhibition of key players of the respiratory burst oxidase system
por: Alfawaz, Bader, et al.
Publicado: (2013)

The impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individuals
por: Dunlea, Danielle M, et al.
Publicado: (2018)

Safety of biweekly α(1)-antitrypsin treatment in the RAPID programme
por: Greulich, Timm, et al.
Publicado: (2018)

The prevalence of alpha-1 antitrypsin deficiency in Ireland
por: Carroll, Tomás P, et al.
Publicado: (2011)

Activation of complement component 3 is associated with airways disease and pulmonary emphysema in alpha-1 antitrypsin deficiency
por: O'Brien, Michael E, et al.
Publicado: (2020)

Cause-specific mortality in individuals with severe alpha 1-antitrypsin deficiency in comparison with the general population in Sweden
por: Tanash, Hanan A, et al.
Publicado: (2016)

The effect of exacerbations on lung density in α(1)-antitrypsin deficiency
por: Strange, Charlie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_j1ehoi0kq739k38ffpnlln1icb